BENAGOL ® Dichlorophenylcarbinol + Amylmetacresol

BENAGOL ® is a drug based on dichlorophenylcarbinol + amylmetacresol

THERAPEUTIC GROUP: Antiseptic of the oral cavity

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications BENAGOL ® Dichlorophenylcarbinol + Amylmetacresol

BENAGOL ® is commonly used as an oral cavity antiseptic.

Mechanism of action BENAGOL ® Dichlorophenylcarbinol + Amylmetacresol

BENAGOL ® is a drug widely used in diseases of the oral cavity and the upper respiratory tract as in the course of pharyngitis, due to its antiseptic properties, evidently guaranteed by the two active ingredients present in it.

In fact both the dichlorophenylcarbinol and the? Amilmetacresol, active ingredients of BENAGOL ®, are active towards numerous pathogenic germs of the oral cavity and of the first respiratory tract, both Gram positive and Gram negative, thus exerting an appreciable antiseptic and bacteriostatic action .

The predominantly local activity, and a modest systemic absorption, also considerably reduce the risk of side effects or clinically relevant drug interactions.

The presence of menthol and other molecules with balsamic activity, perform a modest anesthetic and analgesic action, thus reducing the pain and discomfort that is often associated with infections of the oral cavity and the upper respiratory tract.

Studies carried out and clinical efficacy

DICLOROFENILCARBINOLO E AMILMETACRESOLO E TASTE

Curious work that evaluates the predisposition of small patients to follow therapy with dichlorophenylcarbinol and amylmetacresol according to the tastes of the tablets used.

The greater therapeutic adherence is evidently associated with the clinical finding, thus resulting important in the doctor's therapeutic choices.

LIDOCAINE IN ASSOCIATION WITH DICHLOROFENILCARBINOL AND AMYLETHACRESOL

J Pharm Pharm Sci. 2012 Jan; 15 (2): 281-94.

An interesting study that demonstrates how the addition of lidocaine to the dichlorophenylcarbinol + amylmetacresol association can significantly improve the success of the therapy, guaranteeing a reduction in sore throat in much faster times.

CLINICAL EFFECTIVENESS OF THE DICLOROFENILCARBINOLO AND AMYLMETACRESOL ASSOCIATION

Int J Clin Pract. 2010 Jan; 64 (2): 194-207.

Study that demonstrates how the association between DIchlorophenylcarbinol and Amylmetacresol can guarantee the therapeutic effect in just 2 hours after intake, reducing painful symptoms and lengthening time in the absence of pain.

Method of use and dosage

BENAGOL ®

Tablets with various flavors containing 1.2 mg of Diclrofenicarbinol and 0.6 mg of Amylmetacresol.

We recommend the use of BENAGOL ® for very short periods of time, maximum 3 days, after which, in the absence of appreciable improvements, it would be advisable to consult your doctor and undertake a more aggressive therapy.

Generally, always considering the maximum dose of 8 tablets per day in the adult, it could be useful to slowly dissolve one tablet in the mouth every 3 hours.

Instead, it would be useful to consult your doctor before administering BENAGOL ® in pediatric patients.

Warnings BENAGOL ® Dichlorophenylcarbinol + Amylmetacresol

The use of BENAGOL ®, despite the modest side effects described, should be carried out with particular caution in certain risk categories such as:

patients in pediatric age, for which the presence of triterpene substances could determine the appearance of even serious neurological disorders;
patients with a history of neuropsychiatric disorders.

In order to minimize the possible occurrence of side effects, it would be advisable not to exceed the suggested doses.

BENAGOL ® contains sucrose and glucose, making it therefore not very suitable for patients suffering from saccharase enzyme deficiency, fructose intolerance and glucose-galactose malabsorption.

It is advisable to store the drug out of reach of children and in a cool, dry place.

PREGNANCY AND BREASTFEEDING

The use of BENAGOL ® during pregnancy and in the subsequent period of lactation should be limited to cases of real need and always supervised by your doctor.

The use of BENAGOL ® menthol-eucalyptus in breast-feeding women is contraindicated.

Interactions

Drug interactions worthy of clinical note are currently unknown.

Contraindications BENAGOL ® Dichlorophenylcarbinol + Amylmetacresol

BENAGOL ® is contraindicated in patients who are hypersensitive to the active substance or to one of its many excipients and to children under the age of 2 years.

BENAGOL ® menthol-eucalyptus flavor is also contraindicated in patients with a history of neuropsychiatric disorders.

BENAGOL ® cold mint taste, Ginger and spices is contraindicated in patients under the age of 12 years.